Axatilimab + CAR-T for High-Risk Lymphoma

Axatilimab + CAR-T for High-Risk Lymphoma
Conditions: Diffuse Large B Cell Lymphoma (DLBCL); Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL); High-Grade B-Cell Lymphoma, Nos; PMBCL; Follicular Grade 3 Lymphoma

Interventions: Drug: Axatilimab

Sponsors: Northside Hospital, Inc.

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 11, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments